Replies to post #83388 on Biotech Values

[DewDiligence]

VVUS:

…BIDIL is an excellent example [of a company’s inability to prevent docs from prescribing the constituent generics of a branded combination product]

Agreed with one proviso—I’m not sure BiDil would have sold well under any circumstances because docs just didn’t see the need for the regimen in question.